Dogs should be monitored frequently during sedation for changes in heart rate, blood pressure, respiratory rate and body temperature. Tachycardia may occur in some dogs after recovery from sedation.
In the event of hypoxia or apnea, supplemental oxygen should be administered.
Following administration of Zenalpha, a decrease in body temperature may occur and an external heat source may be needed to maintain body temperature. Hypothermia may persist longer than sedation and analgesia.
The analgesic effect of Zenalpha will not last longer than the sedative effects. Additional analgesic(s) should be administered as needed (see Effectiveness).
Nervous, excited or agitated dogs with high levels of endogenous catecholamines may exhibit a reduced pharmacological response to Zenalpha (ineffectiveness). The onset of sedative/analgesic effects could be slowed, or the depth and duration of effects could be diminished or nonexistent. Therefore, allow the dog to rest quietly for 10 to 15 minutes after injection.
With the alpha2-adrenoceptor agonist drug class, including Zenalpha, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation) exists.
Repeat dosing with Zenalpha has not been evaluated.
Zenalpha has only been evaluated in fasted dogs; therefore, the effects on fed dogs (for example occurrence of vomiting) has not been characterized.
The concurrent use of anticholinergic medications and Zenalpha has not been evaluated.
Zenalpha may decrease serum glucose in healthy dogs and this effect may persist longer than sedation (see Animal Safety).
The safe use of Zenalpha in dogs with hepatic or renal impairment has not been evaluated.
The safe use of Zenalpha has not been evaluated in dogs younger than 4.5 months old.
The safe use of Zenalpha has not been evaluated in dogs that are pregnant, lactating, or intended for breeding.